Golumbeski George 4

What Happened

• George Golumbeski, a director of Acumen Pharmaceuticals, was granted two equity awards on 2026-06-03: 35,500 restricted stock units (RSUs) and a derivative award/option covering 53,250 shares. Both grants show $0 cash consideration in the Form 4 filing.

Key Details

• Transaction date: 2026-06-03; Filing date (Form 4): 2026-06-05 (filed timely).
• Consideration: $0.00 for both awards (typical for compensation grants).
• Vesting: Both awards vest in full on the earlier of the first anniversary of the grant date or the 2027 annual stockholder meeting, subject to Golumbeski’s continuous service through the vesting date (see footnotes F1 and F2).
• Shares owned after the transactions: not provided in the summary excerpt.
• No 10b5-1 plan, tax-withholding sale, or sale/exercise was reported in this filing — these are grants, not purchases or sales.

Context

• RSUs convert to actual shares only upon vesting; the derivative award appears to be an option-like award that also vests on the schedule above. Neither grant represents an immediate market purchase or sale.
• Director equity awards are commonly used as compensation and align interests with shareholders, but they do not necessarily signal near-term buying or selling intentions.